Landscapes / Targets
ALK
13 drugs act on ALK, in 33 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs13
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
ALK inhibitor |
Roche · Public ROG.SW |
Approved | 30 Nov 2026soonPhase 2 trial completes | ||
| Next date | 30 Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung and 3 more | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Roche · Public ROG.SW |
Approved | 30 Nov 2026soonPhase 2 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | 30 Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, Solid Tumors and 3 more | ||||
| Open drug page | |||||
ALK/ROS1 inhibitor |
Pfizer · Public PFE |
Approved | 31 Dec 2026Phase 3 trial completes | ||
| Next date | 31 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | NSCLC, Carcinoma, Non-Small-Cell Lung and 6 more | ||||
| Open drug page | |||||
ROS1/TRK/ALK inhibitor |
Bristol Myers Squibb · Public BMY |
Approved | 16 Feb 2027Phase 3 trial completes | ||
| Next date | 16 Feb 2027 · Phase 3 trial completes | ||||
| Also tested for | Locally Advanced Solid Tumors, Metastatic Solid Tumors and 3 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Novartis · Public NVS |
Approved | 9 Jun 2027Phase 4 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | 9 Jun 2027 · Phase 4 trial completes | ||||
| Also tested for | ALK-positive NSCLC, ALK Positive Malignancies | ||||
| Open drug page | |||||
ALK inhibitor |
Xcovery +1 |
Approved | 1 Feb 2029Phase 1/2 trial completes | ||
| Next date | 1 Feb 2029 · Phase 1/2 trial completes | ||||
| Also tested for | Non-small Cell Lung Cancer, Solid Advanced Tumor | ||||
| Open drug page | |||||
ALK inhibitor |
Phase 3 | Dec 2027Phase 1/2 trial completes | |||
| Next date | Dec 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Locally Advanced Solid Tumor, Metastatic Solid Tumor and 2 more | ||||
| Open drug page | |||||
ALK/ROS1 inhibitor |
Phase 3 | — | |||
| Also tested for | Non-small Cell Lung Cancer, Non Small Cell Lung Cancer | ||||
| Open drug page | |||||
ALK7 siRNA |
Arrowhead · Public ARWR |
Phase 1/2 | Feb 2027Phase 1/2 trial completes | ||
| How it works | A short strand of RNA that switches off one gene | ||||
| Next date | Feb 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Obesity, Type 2 diabetes | ||||
| Open drug page | |||||
— |
Phase 2 | Dec 2027Phase 1/2 trial completes | |||
| Next date | Dec 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumors, Advanced Gastrointestinal Tumors | ||||
| Open drug page | |||||
— |
Phase 1/2 | 31 May 2029Phase 1/2 trial completes | |||
| Next date | 31 May 2029 · Phase 1/2 trial completes | ||||
| Also tested for | ALK-positive NSCLC, ALK-Positive Lung Cancer and 1 more | ||||
| Open drug page | |||||
— |
Phase 1 | May 2027Phase 1 trial completes | |||
| Next date | May 2027 · Phase 1 trial completes | ||||
| Also tested for | Advanced Solid Cancer, Non Small Cell Lung Cancer and 5 more | ||||
| Open drug page | |||||
— |
Phase 1 | 1 Dec 2028Phase 1 trial completes | |||
| Next date | 1 Dec 2028 · Phase 1 trial completes | ||||
| Also tested for | ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 13 of 13 drugs. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026